Afuco™ Anti-Human IL18 ADCC Therapeutic Antibody, ADCC Enhanced
Anti-IL18 ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. AFC-388CL is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). AFC-388CL was generally well tolerated. The most common AEs were nasopharyngitis and headache, arising as frequently in the placebo as in the active drug groups; most AEs were mild to moderate and unrelated to dose level. There were no allergic, delayed-type hypersensitivity, or infusion-related reactions and the incidence of immunogenicity was low.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-388CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | IL18 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |